Investigational Drug Information for SAR443122
✉ Email this page to a colleague
What is the development status for investigational drug SAR443122?
SAR443122 is an investigational drug.
There have been 3 clinical trials for SAR443122.
The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2021.
The most common disease conditions in clinical trials are Coronavirus Infections, Ulcer, and Colitis, Ulcerative. The leading clinical trial sponsors are Sanofi and [disabled in preview].
Summary for SAR443122
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 12 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2021-04-01) |
| Vendors | 0 |
Recent Clinical Trials for SAR443122
| Title | Sponsor | Phase |
|---|---|---|
| Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis | Sanofi | Phase 2 |
| Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus | Sanofi | Phase 2 |
| A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19 | Sanofi | Phase 1 |
Clinical Trial Summary for SAR443122
Top disease conditions for SAR443122
Top clinical trial sponsors for SAR443122
US Patents for SAR443122
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
